Life Science Partner recruits former Director, Analytical Research and Development of Celator Pharmaceuticals Corporation
Life Science Partner announces the appointment of Tom Weber, a pharmaceutical R & D executive, to Angiotech Pharmaceuticals, Inc., as the Director of Analytical Chemistry. Angiotech is a world leader in the emerging field of drug-eluting medical devices and biomaterials. With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Weber will lead the analytical chemistry team to capitalize upon Angiotech’s considerable intellectual property portfolio to create break-through products.
At Celator Pharmaceuticals, an early-stage biopharmaceutical company developing new combination therapies to treat cancer, Weber led the analytical and bioanalytical development of new products through validation, technical transfer and clinical stage product testing. As experienced pharmaceutical scientist, he was previously a senior research and development officer in a several early, mid and development stage pharmaceutical companies.
“Weber brings a wealth of experience in the development of new drugs, drug delivery, drug-congugates and drug-device products which will enable him to immediately contribute to Angiotech’s ongoing projects as well as future developmental programs,” noted Cindi Roberts, Vice President at Life Science Partner.
Weber will lead strategic and tactical direction to the Chemistry group within global R&D across multiple complex device platforms including novel pharmaceutical agents and local delivery technology as well as novel combination product development involving local delivery of device platforms.
Weber received his Bachelor of Arts degree in Chemistry and Physics from Gustavus Adolphus College in St. Peter, Minnesota and his PhD in Chemistry from the University of Minnesota.